scholarly journals Predictors of response to anti‐IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phaseIIclinical trial data

2018 ◽  
Vol 184 (2) ◽  
pp. 232-241 ◽  
Author(s):  
Deanna E. Morra ◽  
Sheila K. Pierson ◽  
Dustin Shilling ◽  
Sepideh Nemat ◽  
Carlos Appiani ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Antibody Therapy ◽  
Castleman Disease ◽  
Trial Data ◽  
Monoclonal Antibody Therapy ◽  
Multicentric Castleman Disease ◽  
Predictors Of Response ◽  
Secondary Analyses

scholarly journals TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy

2021 ◽  
pp. 1359-1365
Author(s):  
Corinne Williams ◽  
Alexis Phillips ◽  
Vikram Aggarwal ◽  
Liron Barnea Slonim ◽  
David C. Fajgenbaum ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Delayed Diagnosis ◽  
Antibody Therapy ◽  
Castleman Disease ◽  
Definitive Diagnosis ◽  
High Morbidity ◽  
Monoclonal Antibody Therapy ◽  
Tafro Syndrome ◽  
Multicentric Castleman Disease ◽  
Effective Treatment Modality

TAFRO syndrome is defined by the presence of thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis/renal dysfunction (R), and organomegaly (O) and can be seen with idiopathic multicentric Castleman disease (iMCD) or as an isolated process without iMCD. Although the diagnosis of iMCD in patients with TAFRO can be challenging to make, iMCD should remain high on the differential diagnosis. Similar to iMCD, the pathophysiology of TAFRO is not well understood but is thought to be related to hypercytokinemia, with interleukin (IL)-6 playing a pivotal role. Anti-IL-6 monoclonal antibody therapy is an effective treatment modality for iMCD, but to date, there is no clear guidance on treatment of TAFRO in the absence of definitive diagnosis of iMCD, leading to suboptimal management and high morbidity. We report a case of TAFRO syndrome and demonstrate benefit with the empiric use of anti-IL-6 antibody therapy in the context of delayed diagnosis of iMCD.

scholarly journals Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections

2021 ◽  
Author(s):  
Hilal Ahmad Parray ◽  
Shivangi Shukla ◽  
Reshma Perween ◽  
Ritika Khatri ◽  
Tripti Shrivastava ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Respiratory Infections ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy
Sign in / Sign up

Export Citation Format

Share Document